Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: A German perspective

Cost Effectiveness and Resource Allocation

Volumn 7, Issue , 2009, Pages

  Scherbaum, Werner A ^a   Goodall, Gordon ^b   Erny Albrecht, Katrina M ^b   Massi Benedetti, Massimo ^c   Erdmann, Erland ^d   Valentine, William J ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b IQVIA   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; PLACEBO; THROMBIN;

ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; GERMANY; HIGH RISK PATIENT; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INCIDENCE; LIFE EXPECTANCY; MACROVASCULAR DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; VASCULAR DISEASE;

EID: 66749159057     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-7-9     Document Type: Article

References (60)

1. Liebl A Kosten in der Früh- und Spätphase des Diabetes mellitus [Costs involved in the early and late phases of diabetes mellitus.] Internist (Berl) 2007, 48:708-714. 10.1007/s00108-007-1875-0 17576527
2. Köster I von Ferber L Ihle P Schubert I Hauner H The cost burden of diabetes mellitus: The evidence from Germany-the CoDiM Study Diabetologia 2006, 49:1498-1504. 10.1007/s00125-006-0277-5 16752168
3. Köster I Hauner H von Ferber L Heterogenität der Kosten bei Patienten mit Diabetes mellitus: Die KoDiM-Studie [Heterogeneity of costs of diabetic patients: The Cost of Diabetes Mellitus Study] Dtsch Med Wochenschr 2006, 131:804-810. 10.1055/s-2006-939850 16607599
4. Liebl A Neiss A Spannheimer A Reitberger U Wagner T Görtz A Kosten des Typ-2-Diabetes in Deutschland [Costs of type 2 diabetes in Germany. Results of the CODE-2 study] Dtsch Med Wochenschr 2001, 126:585-589. 10.1055/s-2001-14102 11402924
5. Yurgin N Secnik K Lage MJ Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: A retrospective database study Clin Ther 2007, 29:316-325. 10.1016/ j.clinthera.2007.02.012 17472823
6. Pittrow D Stalla GK Zeiher AM Silber S März W Pieper L et al [Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care] Med Klin (Munich) 2006, 101:635-644. 10.1007/ s00063-006-1093-x 16896570
7. Schneider CA Herold G Gysan D Albus C Bjarnason-Wehrens B Predel HG Prevalence of cardiovascular risk factors in middle-aged type 2 diabetic automobile employees assessed at the workplace - the Praeford study J Occup Environ Med 2007, 49:481-483. 10.1097/JOM.0b013e3180577750 17495690
8. Krentz AJ Bailey CJ Oral antidiabetic agents: Current role in type 2 diabetes mellitus Drugs 2005, 65:385-411. 10.2165/ 00003495-200565030-00005 15669880
9. Miyazaki Y Mahankali A Matsuda M Glass L Mahankali S Ferrannini E et al Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone Diabetes Care 2001, 24:710-719. 10.2337/diacare.24.4.710 11315836
10. Goldberg RB Kendall DM Deeg MA Buse JB Zagar AJ Pinaire JA et al A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 2005, 28:1547-1554. 10.2337/diacare.28.7.1547 15983299
11. Aljabri K Kozak SE Thompson DM Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: A prospective, randomized trial Am J Med 2004, 116:230-235. 10.1016/j.amjmed.2003.07.023 14969650
12. Hanefeld M Pfützner A Forst T Lübben G Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: A 42-month, open-label, observational, primary care study Curr Med Res Opin 2006, 22:1211-1215. 10.1185/030079906X112598 16846554
13. Derosa G Cicero AF Gaddi A Ragonesi PD Fogari E Bertone G et al Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial Clin Ther 2004, 26:744-754. 10.1016/ S0149-2918(04)90074-4 15220018
14. Gastaldelli A Ferrannini E Miyazaki Y Matsuda M Mari A DeFronzo RA Thiazolidinediones improve beta-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab 2007, 292:E871-E883. 10.1152/ ajpendo.00551.2006 17106061
15. European Medicines Agency Post-Authorisation summary of positive opinion for Glustin (pioglitazone) http://www.emea.europa.eu/pdfs/human/press/pr/ 256803en.pdf
16. Charbonnel B Dormandy J Erdmann E Massi-Benedetti M Skene A The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diabetes Care 2004, 27:1647-1653. 10.2337/diacare.27.7.1647 15220241
17. Dormandy JA Charbonnel B Eckland DJ Erdmann E Massi-Benedetti M Moules IK et al Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial Lancet 2005, 366:1279-1289. 10.1016/S0140-6736(05)67528-9 16214598
18. Kahn SE Haffner SM Heise MA Herman WH Holman RR Jones NP et al Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006, 355:2427-2443. 10.1056/NEJMoa066224 17145742
19. Palmer AJ Roze S Valentine WJ Minshall ME Foos V Lurati FM et al The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement mecision-making Current Medical Research and Opinion 2004, 20:5-26. 10.1185/030079904X1980
20. Palmer AJ Roze S Valentine W Minshall M Foos V Lurati F et al Validation of the CORE Diabetes Model against Epidemiological and Clinical Studies Current Medical Research and Opinion 2004, 20:S27-S40. 10.1185/ 030079904X2006
21. Valentine WJ Bottomley J Palmer AJ Brandle M Foos V Williams R et al PROactive 06: Cost effectiveness of pioglitazone in type 2 diabetes in the UK Diabetic Medicine 2007, 24:982-1002. 10.1111/ j.1464-5491.2007.02188.x 17593245
22. Leibson CL O'Brien PC Atkinson E Palumbo PJ Melton LJ III Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: A population-based study Am J Epidemiol 1997, 146:12-22. 9215219
23. UKPDS Group U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease Diabetes 1995, 44:1249-1258 10.2337/diabetes.44.11.1249 7589820
24. Murabito JM D'Agostino RB Silbershatz H Wilson WF Intermittent claudication. A risk profile from The Framingham Heart Study Circulation 1997, 96:44-49. 9236415
25. Kannel WB D'Agostino RB Silbershatz H Belanger AJ Wilson PW Levy D Profile for estimating risk of heart failure Arch Intern Med 1999, 159:1197-1204. 10.1001/archinte.159.11.1197 10371227
26. Stevens RJ Kothari V Adler AI Stratton IM Holman RR The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56) Clin Sci (Lond) 2001, 101:671-679. 11724655
27. Kothari V Stevens RJ Adler AI Stratton IM Manley SE Neil HA et al UKPDS 60: Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine Stroke 2002, 33:1776-1781. 10.1161/ 01.STR.0000020091.07144.C7 12105351
28. NICE National Institute for Clinical Excellence. Guide to the technology appraisal process http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf Accessed May 2009
29. Graf von der Schulenburg JM Greiner W Jost F KNKMLRMTRHSOVCVtWSWJWCudMdHK (Eds) Deutsche empfehlungen zur gesundheits-ökonomischen evaluation - dritte and aktualisierte fassung des Hannoveraner konsens Gesundh okon Qual Manag 2007, 12:285-290. 10.1055/s-2007-963505
30. Rathmann W Haastert B Icks A Giani G Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004 Diabetes Care 2007, 30:848-853. 10.2337/dc06-2000 17392545
31. Bagust A Beale S Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data Health Econ 2005, 14:217-230. 10.1002/hec.910 15386666
32. Tarn T Smith M Pharmacoeconomic Guidelines Around the World ISPOR Connections 2004, 10:5-15.
33. The UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998, 352:837-853. 10.1016/S0140-6736(98)07019-6 9742976
34. Holstein A Plaschke A Egberts EH Incidence and costs of severe hypoglycemia Diabetes Care 2002, 25:2109-2110. 10.2337/ diacare.25.11.2109 12401771
35. Clarke P Gray A Holman R Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) Med Decis Making 2002, 22:340-349. 12150599
36. Scuffham PA Chaplin S A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention Clin Ther 2005, 27:1467-1477. 10.1016/ j.clinthera.2005.09.012 16291420
37. Briggs AH Wonderling DE Mooney CZ Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation Health Econ 1997, 6:327-340. 10.1002/ (SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W 9285227
38. Köster I von Ferber L Ihle P Schubert I Hauner H The cost burden of diabetes mellitus: The evidence from Germany-the CoDiM Study Diabetologia 2006, 49:1498-1504. 10.1007/s00125-006-0277-5 16752168
39. Wascher TC (Eds) Diabetes Mellitus - How to prevent macrovascular disease? Journal für Kardiol 2003, 10:149-151.
40. Walter H Lübben G Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus Drugs 2005, 65:1-13. 10.2165/00003495-200565010-00001 15610048
41. Schwappach DL Boluarte TA HEE-GER: A systematic review of German economic evaluations of health care published 1990-2004 BMC Health Serv Res 2007, 7:7. 1781069 17222334 10.1186/1472-6963-7-7
42. Eichler HG Kong SX Gerth WC Mavros P Jonsson B Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value in Health 2004, 7:518-528. 10.1111/j.1524-4733.2004.75003.x 15367247
43. Dutch Council for Public Health and Health Care. Sensible and sustainable care http://www.rvz.net/data/download/ Advies_DenZ_samenvatting_engels.doc Accessed March 2008
44. Lucas Goossens. Euro 80,000 per QALY is the limit. Institute for Medical Technology assessment http://www.imta.nl/publications/ imta_newsletter_4_1.pdf Accessed March 2008
45. Devlin N Parkin D Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 2004, 13:437-452. 10.1002/hec.864 15127424
46. Walker S Palmer S Sculpher M The role of NICE technology appraisal in NHS rationing Br Med Bull 2007, 81-82:51-64. 10.1093/bmb/ldm007
47. Bryan S Williams I McIver S Seeing the NICE side of cost-effectiveness analysis: A qualitative investigation of the use of CEA in NICE technology appraisals Health Econ 2007, 16:179-193. 10.1002/hec.1133 16960851
48. Nitschmann S Seufert J [Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)] Internist (Berl) 2007, 48:89-91. 10.1007/s00108-006-1777-6 17187243
49. Institute for Gesundheit und sozialforschung http://www.iges.de
50. DRG prices in Germany 2005
51. Voelkl M Pirk O Juenger V Cost-effectiveness of candesartan in Germany for patients with chronic heart failure Value in Health 2005, 8:A96.
52. Laaser U Breckenkamp J Niermann U Cost-effectiveness analysis of medical interventions in patients with stroke in Germany under special consideration of "stroke units" Gesundh okon Qual Manag 1999, 4:176-183.
53. Dahmen HG [Diabetic foot syndrome and its risks: Amputation, handicap, high-cost sequelae] Gesundheitswesen 1997, 59:566-568. 9453789
54. Köhler A Kölner Kommentar zum EBM 2002 Kölné Deutscher Ärzte-Verlag
55. Andersen HH Schwarze J Bedarfsprofile in der gesetzlichen Krankenversicherung (GKV) [Requirement profiles of statutory health insurance] Berliner Zentrum Public Health 2003
56. Statistisches Bundesamt Deutschland Preisindizes für die Lebenshaltung. Gesundheitsbericht fur Deutschland. Statistisches Bundesamt Deutschland Stuttgart: Metzler Poeschel 1998, 7.8:410-413.
57. Statistisches Bundesamt Deutschland Preisindizes für die Lebenshaltung. Gesundheitsbericht fur Deutschland. Statistisches Bundesamt Deutschland Stuttgart: Metzler Poeschel 1998 5.23 254 258
58. Schädlich PK Brecht JG Brunetti M Pagano E Rangoonwala B Huppertz E Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: Economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance Pharmacoeconomics 2001, 19:497-512. 10.2165/ 00019053-200119050-00005 11465309
59. Kelm-Kahl I Ohrloff C Minimal invasive Chirurgie beim Grauen Star: Was zahlt die Kassee-Medizin and Gesdunheit 2001 http://www3.lifeline.de/ yavivo/Verfahren/Augenheilkunde/Katarakt/35kosten.html Accessed May 2005
60. Ghatnekar O Cost-Effectiveness of treating deep diabetic foot ulcers with Promogran in four different European countries Journal of wound care 2002, 11:70. 11901743